There were a few patients who dropped out due to adverse events but it was a relatively small number. Even more significant, I think, are the patients, especially in the middle dosing arm, who apparently didn't show for their follow up and were therefor counted as failures. Management never adequately explained that in the CC and, although they supposedly revealed that at the shareholders meeting, the information was relayed second-hand by claimed attendees.
Since the only source of that info so far has been from board posters, it is suspect. Management remains publicly mum, despite urgings by at least some investors. Hopefully, they will get their heads out of their bottoms and release a more thorough analysis of the PII results.
